在妇科癌症的发病率、组织学、药物反应、毒性和预后方面存在种族和地区差异。然而，大多数大规模三期研究是在西方国家进行的，对占世界总人口一半以上的亚洲人的数据有限。为了在亚洲建立全球性的临床试验网络，东亚地区的日本妇科肿瘤学组、韩国妇科肿瘤学组、台湾妇科肿瘤学组和中国妇科肿瘤学会于2021年11月19日成立了一个名为东亚妇科肿瘤学试验组(EAGOT)的新组织。它包括四个委员会：子宫颈癌委员会、子宫体癌委员会、卵巢癌委员会和转化医学研究委员会。EAGOT的目的是开展国际临床试验，为受到妇科癌影响的亚洲女性提供最佳治疗。关于新的合作临床试验的讨论已经开始。第一届EAGOT年会于2023年5月25日至27日在日本新潟举行。EAGOT是亚洲妇科癌症领域最大的卫生/调查创新网络，将成为为遭受妇科癌症困扰的亚洲女性制定护理标准和指南的平台。在相近的将来，相关法规/研究者发起的临床试验的协调，以及根据共同协议在四个国家同时批准未经批准的药物和扩大适应症将改善亚洲地区妇科癌症的预后。© 2023. 亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

Racial and regional differences exist in morbidity, histology, drug response, toxicity, and prognosis of gynecologic cancer. However, most large-scale phase III studies have been conducted in Western countries, and these data on Asians, who account for more than half of the world's population, are limited. To build a global clinical trial network in Asia, four clinical trial groups with high expertise and international competitiveness in East Asia, namely the Japanese Gynecologic Oncology Group in Japan, the Korean Gynecologic Oncology Group in Korea, the Taiwanese Gynecologic Oncology Group in Taiwan, and the Chinese Gynecologic Cancer Society in the People's Republic of China, established a new group called the East Asia Gynecologic Oncology Trial Group (EAGOT) on November 19, 2021. It includes four committees: the Cervical Cancer Committee, Uterine Corpus Cancer Committee, Ovarian Cancer Committee, and Translational Research Committee. The purpose of EAGOT is to conduct international clinical trials in an effort to provide the best treatments for Asian women affected by gynecologic cancer. Discussions on new collaborative clinical trials have already begun. The first Annual EAGOT Meeting was held on May 25-27, 2023 in Niigata, Japan. EAGOT, the largest healthcare/investigational innovation network in Asia in the area of gynecologic cancers, will become a platform for establishing standards of care and lead to guidelines for Asian women suffering from gynecologic cancer. The harmonization of regulatory/investigator-initiated clinical trials, simultaneous approval of unapproved drugs in the four countries under a common protocol, and expansion of indications will improve the prognosis of gynecologic cancers in Asia in the near future.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.